Onset and persistence of efficacy by symptom domain with long-acting injectable
paliperidone palmitate in patients with schizophrenia.
Author(s): Alphs L(1), Bossie CA, Fu DJ, Ma YW, Kern Sliwa J.
Affiliation(s): Author information:
(1)Therapeutic Area Leader Psychiatry, Janssen Scientific Affairs, LLC , 1125
Trenton-Harbourton Road-A32404, Titusville, NJ 08560 , USA +1 609 730 3693 ; +1
609 730 3125 ; lalphs@its.jnj.com.
Publication date & source: 2014, Expert Opin Pharmacother. , 15(7):1029-42
INTRODUCTION: Several long-acting injectable (LAI) second-generation
antipsychotics are now available for the management of schizophrenia. As patients
with schizophrenia frequently present with diverse and challenging symptoms, it
is important to understand the effects of antipsychotics in treating these
different symptom subgroups and the timing of these responses.
AREAS COVERED: For this review, data from two randomized, double-blind trials
were analyzed in respect to the onset and persistence of effects on several
measures of psychopathology (as measured by the Positive and Negative Syndrome
Scale [PANSS]) after treatment with LAI paliperidone palmitate (PP) (NCT00590577
and NCT00589914).
EXPERT OPINION: Symptom reductions from baseline with PP were significant by day
4 for all five PANSS factors in both studies. Some effects may have been driven
by the presence or absence of a placebo response. A significant effect for PP
versus placebo was observed for all major symptom domains for one or more doses
of PP during the first month of treatment. Once established, most (but not all)
significant responses persisted to the end point. Similar improvements were
observed in PANSS scores with PP and oral risperidone. Dose-dependent trends were
observed for the effect of PP on positive, negative and uncontrolled
hostility/excitement symptoms.
|